Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 in Combination With Tremelimumab Therapy or MEDI4736 Monotherapy Versus Standard of Care Platinum-Based Chemotherapy in First Line Treatment of Patients With Advanced or Metastatic Non Small-Cell Lung Cancer (NSCLC)(MYSTIC).
Brief Summary: This is a randomized, open-label, multi-center, global, Phase III study to determine the efficacy and safety of MEDI4736 + tremelimumab combination therapy and MEDI4736 monotherapy versus platinum-based SoC chemotherapy in the first-line treatment of patients with epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) wild-type locally advanced or metastatic NSCLC


Options:
A: Arm Label: Dose Escalation; Type: EXPERIMENTAL; Interventions: Drug: MEDI4736, Drug: Tremelimumab | Arm Label: Arm A; Type: EXPERIMENTAL; Interventions: Drug: MEDI4736, Drug: Tremelimumab | Arm Label: Arm B; Type: EXPERIMENTAL; Interventions: Drug: MEDI4736, Drug: tremelimumab | Arm Label: Arm C; Type: EXPERIMENTAL; Interventions: Drug: MEDI4736, Drug: tremelimumab | Intervention Type: DRUG; Name: MEDI4736; Assigned to Arm(s): Arm A, Arm B, Arm C, Dose Escalation | Intervention Type: DRUG; Name: Tremelimumab; Assigned to Arm(s): Arm A, Dose Escalation | Intervention Type: DRUG; Name: tremelimumab; Assigned to Arm(s): Arm B, Arm C
B: Arm Label: Pembrolizumab; Type: EXPERIMENTAL; Interventions: Biological: pembrolizumab | Arm Label: SOC Treatment; Type: ACTIVE_COMPARATOR; Interventions: Drug: carboplatin, Drug: paclitaxel, Drug: pemetrexed | Intervention Type: BIOLOGICAL; Name: pembrolizumab; Assigned to Arm(s): Pembrolizumab | Intervention Type: DRUG; Name: carboplatin; Assigned to Arm(s): SOC Treatment | Intervention Type: DRUG; Name: paclitaxel; Assigned to Arm(s): SOC Treatment | Intervention Type: DRUG; Name: pemetrexed; Assigned to Arm(s): SOC Treatment
C: Arm Label: Monotherapy; Type: EXPERIMENTAL; Interventions: Biological: MEDI4736 (Durvalumab) | Arm Label: Combination Therapy; Type: EXPERIMENTAL; Interventions: Biological: MEDI4736 (Durvalumab)+Tremelimumab, Biological: Tremelimumab | Arm Label: Standard of Care; Type: ACTIVE_COMPARATOR; Interventions: Drug: Paclitaxel + Carboplatin, Drug: Gemcitabine + Cisplatin, Drug: Gemcitabine + Carboplatin, Drug: Pemetrexed + Cisplatin, Drug: Pemetrexed + Carboplatin | Intervention Type: BIOLOGICAL; Name: MEDI4736 (Durvalumab); Assigned to Arm(s): Monotherapy | Intervention Type: BIOLOGICAL; Name: MEDI4736 (Durvalumab)+Tremelimumab; Assigned to Arm(s): Combination Therapy | Intervention Type: DRUG; Name: Paclitaxel + Carboplatin; Assigned to Arm(s): Standard of Care | Intervention Type: DRUG; Name: Gemcitabine + Cisplatin; Assigned to Arm(s): Standard of Care | Intervention Type: DRUG; Name: Gemcitabine + Carboplatin; Assigned to Arm(s): Standard of Care | Intervention Type: DRUG; Name: Pemetrexed + Cisplatin; Assigned to Arm(s): Standard of Care | Intervention Type: DRUG; Name: Pemetrexed + Carboplatin; Assigned to Arm(s): Standard of Care | Intervention Type: BIOLOGICAL; Name: Tremelimumab; Assigned to Arm(s): Combination Therapy
D: Arm Label: Nivolumab+Ipilimumab; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab, Biological: Ipilimumab | Arm Label: Nivolumab+Ipilimumab + 2 cycles Platinum Doublet Chemotherapy; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab, Biological: Ipilimumab, Drug: Platinum Doublet Chemotherapy | Intervention Type: BIOLOGICAL; Name: Nivolumab; Assigned to Arm(s): Nivolumab+Ipilimumab, Nivolumab+Ipilimumab + 2 cycles Platinum Doublet Chemotherapy | Intervention Type: BIOLOGICAL; Name: Ipilimumab; Assigned to Arm(s): Nivolumab+Ipilimumab, Nivolumab+Ipilimumab + 2 cycles Platinum Doublet Chemotherapy | Intervention Type: DRUG; Name: Platinum Doublet Chemotherapy; Assigned to Arm(s): Nivolumab+Ipilimumab + 2 cycles Platinum Doublet Chemotherapy

Answer: C